LBIO (Longevity Biomedical) Total Receivables: $0.00 Mil (As of . 20)


What is Longevity Biomedical Total Receivables?

Longevity Biomedical LBIO Total Receivables is $0.00 Mil as of . 20.

Longevity Biomedical's Total Receivables for the quarter that ended in . 20 was $0.00 Mil.

Longevity Biomedical Total Receivables Related Terms

Longevity Biomedical Total Receivables Historical Data

* Premium members only.

The historical data trend for Longevity Biomedical's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical Total Receivables Chart

Longevity Biomedical Annual Data
Trend
Total Receivables

Longevity Biomedical Semi-Annual Data
Total Receivables

Longevity Biomedical Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.00 Mil mean?
Longevity Biomedical (LBIO) has a Total Receivables of $0.00 Mil as of . 20. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Longevity Biomedical and its competitors.
Is Longevity Biomedical's Total Receivables too high?
Longevity Biomedical's current Total Receivables is $0.00 Mil.
How does Longevity Biomedical's Total Receivables compare to ?
Longevity Biomedical's Total Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Longevity Biomedical and its competitors. Longevity Biomedical's current Total Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Biomedical stock overvalued right now?
Longevity Biomedical (LBIO) has a current Total Receivables of $0.00 Mil. The current Total Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Longevity Biomedical (LBIO), the current Total Receivables is $0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Biomedical Business Description

Comparable Companies
Address 12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.